• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

传统非房室方程估算基本药代动力学参数的准确性及基于正常受试者数据预测肥胖患者稳态分布容积。

On the accuracy of estimation of basic pharmacokinetic parameters by the traditional noncompartmental equations and the prediction of the steady-state volume of distribution in obese patients based upon data derived from normal subjects.

机构信息

Genentech Inc, South San Francisco, California 94080, USA.

出版信息

J Pharm Sci. 2011 Jun;100(6):2482-97. doi: 10.1002/jps.22444. Epub 2011 Jan 19.

DOI:10.1002/jps.22444
PMID:21254063
Abstract

The steady-state and terminal volumes of distribution, as well as the mean residence time of drug in the body (V(ss), V(β), and MRT) are the common pharmacokinetic parameters calculated using the drug plasma concentration-time profile C(p) (t) following intravenous (i.v. bolus or constant rate infusion) drug administration. These calculations are valid for the linear pharmacokinetic system with central elimination (i.e., elimination rate being proportional to drug concentration in plasma). Formally, the assumption of central elimination is not normally met because the rate of drug elimination is proportional to the unbound drug concentration at elimination site, although equilibration between systemic circulation and the site of clearance for majority of small molecule drugs is fast. Thus, the assumption of central elimination is practically quite adequate. It appears reasonable to estimate the extent of possible errors in determination of these pharmacokinetic parameters due to the absence of central elimination. The comparison of V(ss), V(β), and MRT calculated by exact equations and the commonly used ones was made considering a simplified physiologically based pharmacokinetic model. It was found that if the drug plasma concentration profile is detected accurately, determination of drug distribution volumes and MRT using the traditional noncompartmental calculations of these parameters from C(p) (t) yields the values very close to that obtained from exact equations. Though in practice, the accurate measurement of C(p) (t), especially its terminal phase, may not always be possible. This is particularly applicable for obtaining the distribution volumes of lipophilic compounds in obese subjects, when the possibility of late terminal phase at low drug concentration is quite likely, specifically for compounds with high clearance. An accurate determination of V(ss) is much needed in clinical practice because it is critical for the proper selection of drug treatment regimen. For that reason, we developed a convenient method for calculation of V(ss) in obese (or underweight) subjects. It is based on using the V(ss) values obtained from pharmacokinetic studies in normal subjects and the physicochemical properties of drug molecule. A simple criterion that determines either the increase or decrease of V(ss) (per unit body weight) due to obesity is obtained. The accurate determination of adipose tissue-plasma partition coefficient is crucial for the practical application of suggested method.

摘要

稳态和末端分布容积以及药物在体内的平均驻留时间(V(ss)、V(β)和 MRT)是使用静脉内(i.v. 推注或恒速输注)药物给药后药物血浆浓度-时间曲线 C(p)(t)计算的常见药代动力学参数。这些计算适用于具有中央消除的线性药代动力学系统(即消除速率与血浆中药物浓度成正比)。从理论上讲,中央消除的假设通常不成立,因为药物消除速率与消除部位的未结合药物浓度成正比,尽管对于大多数小分子药物,全身循环与清除部位之间的平衡速度很快。因此,中央消除的假设在实践中是相当充分的。由于缺乏中央消除,估计这些药代动力学参数确定中可能存在的误差程度似乎是合理的。考虑到简化的基于生理的药代动力学模型,比较了使用精确方程和常用方程计算的 V(ss)、V(β)和 MRT。结果发现,如果准确检测药物血浆浓度曲线,则使用这些参数的传统非隔室计算从 C(p)(t) 计算药物分布容积和 MRT 会得到非常接近从精确方程获得的值。尽管实际上,特别是在终端阶段,准确测量 C(p)(t)可能并不总是可行的。当药物浓度低时,很可能出现晚期终端阶段,特别是对于清除率高的化合物,这种情况在肥胖患者中获得亲脂性化合物的分布容积时尤其适用。在临床实践中,准确确定 V(ss)非常重要,因为它是正确选择药物治疗方案的关键。为此,我们开发了一种方便的方法来计算肥胖(或消瘦)患者的 V(ss)。它基于使用从正常受试者的药代动力学研究中获得的 V(ss)值和药物分子的物理化学性质。获得了一个简单的标准,该标准确定肥胖导致 V(ss)(每单位体重)增加还是减少。准确确定脂肪组织-血浆分配系数对于建议方法的实际应用至关重要。

相似文献

1
On the accuracy of estimation of basic pharmacokinetic parameters by the traditional noncompartmental equations and the prediction of the steady-state volume of distribution in obese patients based upon data derived from normal subjects.传统非房室方程估算基本药代动力学参数的准确性及基于正常受试者数据预测肥胖患者稳态分布容积。
J Pharm Sci. 2011 Jun;100(6):2482-97. doi: 10.1002/jps.22444. Epub 2011 Jan 19.
2
On the accuracy of calculation of the mean residence time of drug in the body and its volumes of distribution based on the assumption of central elimination.基于中央消除假设对药物在体内的平均驻留时间及其分布容积计算的准确性
Xenobiotica. 2016;46(6):477-82. doi: 10.3109/00498254.2015.1089366. Epub 2015 Sep 25.
3
The connection between the steady state (Vss) and terminal (Vbeta) volumes of distribution in linear pharmacokinetics and the general proof that Vbeta >/= Vss.线性药代动力学中稳态分布容积(Vss)与终末分布容积(Vβ)之间的关系以及Vβ≥Vss的一般证明。
J Pharm Sci. 2007 Jun;96(6):1638-52. doi: 10.1002/jps.20804.
4
The influence of hepatic transport on the distribution volumes and mean residence time of drug in the body and the accuracy of estimating these parameters by the traditional pharmacokinetic calculations.肝转运对药物在体内分布容积和平均驻留时间的影响,以及传统药代动力学计算估算这些参数的准确性。
J Pharm Sci. 2011 Nov;100(11):5031-47. doi: 10.1002/jps.22696. Epub 2011 Jul 15.
5
Prediction of drug terminal half-life and terminal volume of distribution after intravenous dosing based on drug clearance, steady-state volume of distribution, and physiological parameters of the body.基于药物清除率、稳态分布容积和机体生理参数预测静脉给药后的药物末端半衰期和末端分布容积。
J Pharm Sci. 2013 Feb;102(2):761-71. doi: 10.1002/jps.23396. Epub 2012 Dec 11.
6
Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination.具有外周消除的线性药代动力学系统的稳态分布容积。
J Pharm Sci. 2004 Jun;93(6):1628-40. doi: 10.1002/jps.20073.
7
Determination of mean residence time of drug in plasma and the influence of the initial drug elimination and distribution on the calculation of pharmacokinetic parameters.药物在血浆中平均驻留时间的测定以及初始药物消除和分布对药代动力学参数计算的影响。
J Pharm Sci. 2009 Feb;98(2):748-62. doi: 10.1002/jps.21440.
8
On the determination of the time delay in reaching the steady state drug concentration in the organ compared to plasma.关于确定器官中药物浓度达到稳态相较于血浆的时间延迟。
J Pharm Sci. 2007 Dec;96(12):3432-43. doi: 10.1002/jps.20986.
9
Prediction of human oral plasma concentration-time profiles using preclinical data: comparative evaluation of prediction approaches in early pharmaceutical discovery.应用临床前数据预测人体口腔血浆浓度-时间曲线:早期药物发现中预测方法的比较评估。
Clin Pharmacokinet. 2011 Aug;50(8):505-17. doi: 10.2165/11587230-000000000-00000.
10
A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein-bound drugs and the impact of errors in plasma protein binding.一种基于生理学的药代动力学模型,用于预测高蛋白结合药物的药代动力学以及血浆蛋白结合误差的影响。
Biopharm Drug Dispos. 2016 Apr;37(3):123-41. doi: 10.1002/bdd.1996.

引用本文的文献

1
Obesity and its Relationship with Covid-19: A Review of the Main Pharmaceutical Aspects.肥胖与新冠肺炎的关系:主要药物学方面的综述。
Curr Pharm Biotechnol. 2024;25(13):1651-1663. doi: 10.2174/0113892010264503231108070917.
2
Comparison of different weight-based scalars of remimazolam tosylate for anesthesia induction in obese patients: study protocol for a prospective, controlled trial.比较肥胖患者中不同基于体重的甲苯磺酸雷米唑仑标度用于麻醉诱导的效果:一项前瞻性、对照试验的研究方案。
Trials. 2023 Nov 10;24(1):719. doi: 10.1186/s13063-023-07739-6.
3
Efficacious Cefazolin Prophylactic Dose for Morbidly Obese Women Undergoing Bariatric Surgery Based on Evidence from Subcutaneous Microdialysis and Populational Pharmacokinetic Modeling.
基于皮下微透析和群体药代动力学模型的证据,为病态肥胖女性接受减重手术时头孢唑林的有效预防剂量。
Pharm Res. 2018 Apr 11;35(6):116. doi: 10.1007/s11095-018-2394-5.
4
Toxicological function of adipose tissue: focus on persistent organic pollutants.脂肪组织的毒理学作用:以持久性有机污染物为重点。
Environ Health Perspect. 2013 Feb;121(2):162-9. doi: 10.1289/ehp.1205485. Epub 2012 Dec 5.